1. Introduction {#sec1}
===============

Clopidogrel is a common antiplatelet agent used as an alternative for aspirin or in dual antiplatelet therapy with aspirin \[[@B1]--[@B3]\]. Clopidogrel irreversibly inhibits adenosine diphosphate, which is necessary for platelet aggregation while aspirin works through inactivation of the enzyme cyclooxygenase. Both drugs prevent clot formation for the lifetime of the platelet, which is 9--11 days \[[@B4], [@B5]\].

When patients under such antiplatelet therapy need surgery, the surgeon is confronted with the choice of interrupting the therapy, which increases the risks of thrombosis, or continuing the medication, which on the other hand increases the risk of hemorrhage. Published studies commonly recommended continuation of antiplatelet drugs for minor oral surgery \[[@B3], [@B6], [@B7]\]. However, a perioperative interruption of antiplatelet medication is still frequently practiced for dental procedures \[[@B8]\]. In particular, clopidogrel, either for single or dual therapy, is feared for exposing patients to a high risk of bleeding \[[@B9]\] since it takes 5--10 days for full recovery of platelet activity after withdrawal.

The purpose of this study is to evaluate the postoperative bleeding rate for oral osteotomy and other invasive oral procedures under continued monoclopidogrel therapy or dual clopidogrel/aspirin therapy. We focus on oral osteotomy because this procedure involves invading the bone and therefore has a higher bleeding risk than other minor oral procedures such as tooth extraction.

2. Materials and Methods {#sec2}
========================

A total of 405 oral osteotomy procedures were followed for 2 weeks. Some patients underwent multiple procedures. Each procedure was counted as an independent case (not the number of the patients) and subsequent analysis was based on this definition. A total of 64 procedures were carried out in patients who were under monoantiplatelet treatment with clopidogrel (75 mg/day) and another 60 procedures in patients under dual antiplatelet medication with clopidogrel (75 mg/day) and aspirin (100 mg/day). In all these 124 cases, medication was continued as usual and no change, neither interruption, reduction, nor bridging, was conducted. The rest of 281 osteotomy procedures were carried out in patients who were not under any anticoagulation or antiplatelet treatment.

All procedures were carried out by the senior author himself under local anaesthesia with articaine 4% and epinephrine 1 : 200.000 (Ultracaine D-S, Sanofi-Aventis) on an outpatient basis. In case of contraindications to epinephrine, scandicain 4% (Scandicain 4%, AstraZeneca) was used. After osteotomy, meticulous curettage of the extraction socket was performed and all of granulation tissue removed. Local hemostasis was achieved with a collagen fleece; wound closure was carried out with sutures and an acrylic splint. All patients received a single shot of 1000 mg amoxycillin as a prophylactic antibiotic measure. Postoperative pain was treated with ibuprofen 400 mg every 6 hours for 3 days or further if needed. Patients were routinely seen on the first, third, seventh, tenth, and 14th day. A bleeding was defined as an event that required additional surgical intervention.

Patient data were recorded using Evident (Evident, Bingen, Germany) and evaluated using SPSS. Confidence interval for bleeding incidence was calculated for 95% level \[[@B10]\].

3. Results {#sec3}
==========

Postoperative bleeding was generally rare. Among the 281 osteotomy procedures for patients not under any antiplatelet medication, bleeding occurred only in 2 (0.7%) cases with a 95% confidence interval of 0.2--2.6%. For the 64 and 60 procedures under continued mono- and dual antiplatelet therapy, postoperative bleeding occurred in 1 (1.6%) and 2 (3.3%) cases, with 95% confidence intervals of 0.3--8.3% and 0.9--11.3%, respectively. The bleeding rates were not significantly higher in the mono- and dual antiplatelet treatment groups compared to that in the group of nonanticoagulation ([Table 1](#tab1){ref-type="table"}). However, the statistical powers were only 0.18 and 0.45.

All bleedings occurred within 48 hours after the operation. For 4 out of the 5 bleeding cases, local measures with pressure on the osteotomy wound with methyloxycellulose was sufficient to achieve hemostasis. For the last case, fibrin glue (Tissucol Duo S, Baxter) was applied in addition to the methyloxycellulose. No change of the antiplatelet medication, no transfusion of blood, nor hospital admittance was necessary.

4. Discussion {#sec4}
=============

The postoperative bleeding rate for osteotomy in the present study was generally low and was only slightly increased for cases under continued mono- and dual clopidogrel therapies (from 0.7% to 1.6% and 3.3%, resp.). However, due to the small sample size, especially that of the two therapy groups, the statistical powers were extremely low (0.18 and 0.45). The results of the present study are therefore of preliminary nature. Due to the small sample size, the data are not sufficient for detecting small differences in postoperative bleeding rates. At a 95% confidence level, the ranges of the bleeding rates can be estimated as below 8.3% and 11.3% for the mono- and dual therapy cases, respectively. With larger sample size in future studies, we expect to narrow down these ranges.

We have demonstrated that the bleedings were all manageable with simple local measures without stopping or modifying the anticoagulation therapy. This may ease the fear of lacking immediate countermeasures for clopidogrel to some extent \[[@B6], [@B11], [@B12]\].

For minor oral surgery such as teeth extraction, increasing data suggests that continuing antiplatelet medication during oral surgery does not increase the bleeding risk notably whereas the role of local hemostasis is emphasized \[[@B13], [@B14]\]. However, only very limited cases involved clopidogrel \[[@B15]--[@B17]\]. For example, Park et al. \[[@B18]\] observed 1.7% (1/59) excessive intraextraction bleeding under continued dual antiplatelet therapy but failed to follow up the patients for subsequent bleeding incidences. Girotra et al. \[[@B19]\] reported 5.2% immediate postoperative bleeding for oral surgery (mostly dental extraction) with continued monoclopidogrel and 7.9% for dual clopidogrel therapies. Oral osteotomy is more invasive than minor oral procedures such as standard teeth extraction. Nevertheless, the postoperative bleeding rates of 1.6% and 3.3% under continued mono- and dual clopidogrel therapy in our study are comparable or even below the already published ones.

We have recently followed bleeding for similar procedures under continued aspirin and phenprocoumon therapy and obtained the rates of 1.6% and 7.4%, respectively. Our findings confirm that the postoperative bleeding rates under continued anticoagulation therapy vary depending on the target of the therapy and the used reagents \[[@B20]--[@B22]\]. In case of continued phenprocoumon therapy, surgeons should be more cautious. By contrast, continuing antiplatelet therapy with aspirin and clopidogrel is likely safer.

In any case, preventive measures are recommendable for oral osteotomy under continued antiplatelet therapy. For example, we close the wound using a collagen sponge and sutures and further covered the site with an acrylic splint. Others pointed out possible timing effect and suggested the beginning of the week and morning hours for the surgery \[[@B13], [@B23]\]. Since most bleeding events are within 2 days after the surgery, a 24-hour hotline for two days may provide an effective measure ensuring quick response in case of bleeding.

5. Conclusion {#sec5}
=============

Our results suggest that, despite its more invasive nature, oral osteotomy can be performed safely under continued monoantiplatelet medication with clopidogrel or dual antiplatelet medication with clopidogrel/aspirin.
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Clinical features and bleeding rates in control and antiplatelet groups.

  Features and Parameters                          Antiplatelet medication   Chi-test, *t*-test (control versus mono-/dual therapy group)                                            
  ------------------------------------------------ ------------------------- -------------------------------------------------------------- --------------------- ------------------ -----------
  Group                                            Control                   Clopidogrel                                                    Clopidogrel/Aspirin   Significance *P*   Power
  Number of cases                                  281                       64                                                             60                                        
  Postoperative bleeding                                                                                                                                                              
   Case                                            2                         1                                                              2                                         
   Rate (95% confidence)                           0.7% (0.2--2.6%)          1.6% (0.3--8.3%)                                               3.3% (0.9--11.3%)     0.46/0.14          0.18/0.45
  Age (years)                                      60.7 ± 6.3                67.9 ± 14.6                                                    64.0 ± 10.8           \<0.00/\<0.00      0.98/0.74
  Male/female                                      129/152                   35/29                                                          44/16                 0.21/0.00          0.24/0.98
  Numbers of teeth                                 1.7 ± 1.8                 1.5 ± 0.8                                                      1.5 ± 1.1             0.32/0.38          0.39/0.30
  Dose                                                                       75 mg/day                                                      75 mg + 100 mg/day                        
  Indication for antithrombotic medication                                                                                                                                            
   Apoplexy + TIA                                                            6                                                              7                     0.15                
   Stent + bypass                                                            16                                                             28                                       
   Myocardial infarction + other heart disorders                             12                                                             13                                       
   Others                                                                    3                                                              3                                        
   Unknown                                                                   27                                                             9                                         
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